TC
GEVA

Travelers Companies’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Travelers Companies’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,965
Closed -$82K – 39
2013
Q2 		$82K Buy
+1,965
New +$89.5K 0.02% 32

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Travelers Companies's GEVA Position: Q3 2013 in Review

Travelers Companies sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2013, closing a stake of 1,965 shares — an estimated $82K sold.

Travelers Companies first reported a position in GEVA in Q2 2013 and held it in 1 quarter. The position peaked at $82K in Q2 2013. 95 funds tracked by Wall St. Rank hold GEVA as of Q3 2013.

  • Travelers Companies reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Travelers Companies sold 1,965 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2013, an estimated $82K.
  • Travelers Companies first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Travelers Companies's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $82K in Q2 2013.
  • 95 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2013.

Based on Travelers Companies's 13F filing for Q3 2013, filed 14 Nov 2013.